University of Ioannina
Μελέτη της ανάπτυξης φαρμακοεπαγώμενων υπερκινησιών σε πειραματικά μοντέλα νόσου Πάρκισον
Abstract
dc:descriptionLong-term levodopa replacement therapy in Parkinson’s disease is confounded by abnormal involuntary movements, known as Levodopa Induced Dyskinesia (LID). Dysfunctional glutamatergic neurotransmission has been implicated in the pathogenesis of LID making metabotropic and ionotropic glutamate receptors attractive novel therapeutic targets. The objective was to investigate the antidyskinetic site of action of different glutamate receptor antagonists in the brain. For that purpose, receptor antagonists were administered by intracerebral infusion in the caudate-putamen (CPu), the substantia nigra zona reticulata (SNr) or the subthalamic nucleus (STN) of 6-OHDA-lesioned rats exhibiting LID. Τhe striatum proved important in the antidyskinetic action of NMDA and AMPA receptor antagonists. The metabotropic receptor antagonist demonstrated ani-dykinetic action after administration in subthalamic nucleus. This fact highlights the importance of the metabotropic glutamate receptors that reside in the STN as future therapeutic targets in the treatment of LID.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Maranis, Sotirios
- Μαρανής, Σωτήριος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45014